Semaglutide's molecular structure: what the science actually tells us

What exactly is semaglutide made of, structurally?

Semaglutide belongs to a class of compounds called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating; it signals to the brain that you are full, slows the rate at which the stomach empties, and stimulates insulin release when blood glucose rises. Natural GLP-1 is cleared from the bloodstream within a few minutes, which makes it useless as a medicine in its native form.

To get around this, Novo Nordisk's chemists built semaglutide by starting with a 34-amino-acid backbone that closely follows human GLP-1, then making three key structural changes. First, the amino acid at position 8 was swapped for one that the enzyme DPP-4 cannot easily cleave, protecting the molecule from rapid degradation. Second, position 34 was altered to allow attachment of the third modification: a C-18 fatty-diacid chain, tethered via a short linker. That fatty-acid tail binds non-covalently to albumin (the most abundant protein in blood) effectively turning the drug into a long-lasting depot that circulates for days rather than minutes. You can read more about the peptide architecture on our semaglutide molecule overview.

The result is a molecule with a plasma half-life of approximately seven days, which is why one injection per week maintains a steady therapeutic level. That steady level, rather than peaks and troughs, is what underpins the consistent appetite suppression reported in clinical trials of Wegovy.

Why does the molecular weight of semaglutide matter in practice?

At roughly 4,113.6 Da, semaglutide sits in the category chemists call a mid-size biologic, too large and polar to diffuse passively across the gut wall the way a small-molecule tablet would. This is the fundamental reason Wegovy has historically been an injection: subcutaneous delivery deposits the drug directly into tissue, where it is absorbed into the lymphatic and then the vascular system without needing to survive the harsh enzymatic environment of the stomach intact.

The molecular weight of semaglutide also shapes how it distributes in the body. Because it binds tightly to albumin, it stays largely in the bloodstream and interstitial fluid rather than penetrating cells or crossing the blood-brain barrier directly. Its action on appetite centres in the hypothalamus appears to occur via GLP-1 receptors in the area postrema and vagal afferents, regions where the blood-brain barrier is less restrictive.

Oral delivery was long considered impractical for molecules of this size. The approved oral formulation (Wegovy tablets) gets around this by co-formulating semaglutide with SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), an absorption enhancer that transiently raises local gastric pH and facilitates transcellular uptake across the stomach lining. Even so, bioavailability is lower than the injection, which is why the oral maintenance dose (25 mg) is far higher in mass terms than the injection's 2.4 mg. Our page on the semaglutide molecular formula covers the elemental composition in more detail.

How does semaglutide's structure compare with tirzepatide's?

A question our prescribers hear regularly is how Wegovy's mechanism differs from Mounjaro's. Tirzepatide is also a peptide analogue, but it is a dual agonist: it activates both the GLP-1 receptor and the GIP receptor simultaneously. Structurally, it is based on the native GIP sequence rather than GLP-1, with modifications that allow it to bind both receptors. Semaglutide, by contrast, is selective for GLP-1 receptors only.

Whether that dual action translates to meaningfully different outcomes for a given individual is a clinical question, not a chemistry one. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, found that tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks, though the gap narrowed at semaglutide's newer 7.2 mg dose. The Wegovy overview covers the approved doses and what the evidence says about each. For a broader look at how semaglutide works in a clinical context, see our semaglutide guide.

From a structural standpoint, both molecules use the same core engineering principle (a modified peptide backbone with a fatty-acid extension for albumin binding and a long half-life) which is why both are dosed once weekly. The difference lies in which receptor each one prioritises and how the linker chemistry is arranged. Neither is a simple small-molecule drug; both require subcutaneous injection in their primary approved formulations.

Does the molecular structure affect who semaglutide is suitable for?

The structure itself does not determine eligibility directly, but it does explain some of the practical considerations prescribers weigh. Because semaglutide slows gastric emptying, it can affect how quickly other oral medicines (including the contraceptive pill) are absorbed. NHS guidance specifically notes this interaction, and women using oral contraception should discuss additional precautions with their prescriber at the outset of treatment.

The size and route of the molecule are also why storage matters: the injectable formulation must be refrigerated at 2–8°C, and the exact room-temperature window before a pen is discarded is set out in the Patient Information Leaflet rather than approximate rules of thumb. If you are thinking about treatment around a holiday or a period when fridge access is uncertain, that is worth raising during your consultation. The chemical structure breakdown goes into more detail on stability.

Eligibility for Wegovy in the UK is based on BMI (30 or above, or 27–29.9 with a weight-related health condition), age (adults only), and a full medical assessment. The treatment page at nume outlines the process. As the NHS patient information for semaglutide makes clear, this is a prescription-only medicine; a qualified prescriber, not a screening algorithm, determines whether it is right for a given patient. For a broader look at options, the weight-loss overview sets out the landscape. Our clinical team can answer questions specific to your situation.